ConcertAI’s TeraRecon Launches DETECT to Align AI Imaging With Reimbursement and Clinical Workflow
ConcertAI’s TeraRecon division has launched DETECT, an AI-first platform designed to close the gap between imaging innovation and reimbursement.
ConcertAI’s TeraRecon division has launched DETECT, an AI-first platform designed to close the gap between imaging innovation and reimbursement.
Germany issued two significant regulatory updates: the G-BA expanded its emergency-care tier system by adding a new “non-participation” level, and IQWiG reported that daratumumab shows no proven survival benefit in smoldering multiple myeloma due to flaws in the comparator arm of the AQUILA study.
CMS has set national pricing for the inFlow Voiding Prosthesis in the 2026 Medicare fee schedule, expanding access to the only alternative to lifelong catheter use for women with permanent urinary retention.
NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
Synopulse’s NeuroPulse Daily tracks major movements across neurology, including new Parkinson’s diagnostics, ALS care funding, Huntington’s genetic medicine progress, AI-powered imaging clearance, breakthrough neurotechnology, and multimillion-dollar collaborations accelerating CNS drug discovery.
Valo Health has entered a collaboration with Merck KGaA, Darmstadt, Germany worth over $3 billion to accelerate AI-driven discovery of Parkinson’s disease therapies.
Minnesota applied for $1B under the federal Rural Health Transformation Program to strengthen rural hospitals, telehealth, and workforce capacity.
The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
Today’s neurology roundup highlights momentum across Alzheimer’s and ALS drug development, spinal cord injury research, intravascular imaging, and next-gen MRI technologies.